Interações de Eslicarbazepina

CYP3A4 Inducers: Avoid concomitant strong CYP3A4 inducers during YONSA treatment. (bula de Abiraterona, Interações medicamentosas)

• CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (bula de Acalabrutinibe, Interações medicamentosas)

Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Ácido valproico, Advertência em caixa preta)

Combinar álcool com medicamentos sedativos (opioides, benzodiazepínicos, medicamentos para dormir, relaxantes musculares) pode causar sonolência perigosa, respiração lenta e superdose. (NIAAA, Harmful Interactions: Mixing Alcohol with Medicines)

CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (bula de Alpelisibe, Interações medicamentosas)

• Effects on Driving and Operating Machinery: Patients receiving • alprazolam XR should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (bula de Alprazolam, Advertências e precauções)

• Simultaneous use of combined P-gp and strong CYP3A4 inducers reduces blood levels of apixaban: Avoid concomitant use. (bula de Apixabana, Interações medicamentosas)

Drug Interactions : Use with strong cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended because loss of efficacy may occur ( 5.5 , 7.1 ) (bula de Apremilaste, Advertências e precauções)

CYP3A4 Inducers : Avoid concomitant use for greater than 14 days ( 7.1 ) (bula de Aripiprazol, Interações medicamentosas)

• when coadministered with drugs that are strong inducers of CYP3A due to the potential for loss of therapeutic effect and development of resistance. (bula de Atazanavir, Contraindicações)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (bula de Azelastina + fluticasona, Advertências e precauções)

…AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH ALCOHOL, BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Belladonna and opium suppositories expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (bula de Beladona + ópio, Advertência em caixa preta)

Concomitant administration of BIXLENVO is contraindicated with: dofetilide due to the potential for increased dofetilide plasma concentrations and associated serious and/or life-threatening events. strong CYP3A inducers due to decreased plasma concentrations of BIC and LEN, which may result in the loss of therapeutic effect and development of resistance to BIXLENVO. (bula de Bictegravir + entricitabina + tenofovir alafenamida, Contraindicações)

Strong CYP3A4 Inducers: Avoid concomitant use. (bula de Bortezomibe, Interações medicamentosas)

• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (bula de Bosutinibe, Interações medicamentosas)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Buprenorfina, Advertência em caixa preta)

Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions (5.3) and Drug Interactions (7.3)] . (bula de Bupropiona, Contraindicações)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Butalbital + ácido acetilsalicílico + cafeína + codeína, Advertência em caixa preta)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Butalbital + paracetamol + cafeína + codeína, Advertência em caixa preta)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Butorfanol, Advertência em caixa preta)

…diphosphate glucuronosyltransferase (UGT)1A1 enzyme induction, which may result in loss of virologic response [see Drug Interactions ( 7.2 , 7.3 ), Clinical Pharmacology ( 12.3 )] : o Anticonvulsants: Carbamazepine, oxcarbazepine, phenobarbital, phenytoin o Antimycobacterials: Rifampin, rifapentine Prior to initiation of VOCABRIA, note that use of CABENUVA (cabotegravir… (bula de Cabotegravir, Contraindicações)

Avoid chronic co-administration of strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. (bula de Cabozantinibe, Interações medicamentosas)

Serious and sometimes fatal dermatologic reactions, including TEN and SJS, have also been reported in patients using oxcarbazepine or carbamazepine which are chemically related to APTIOM. (bula de Eslicarbazepina, Advertências e precauções)

Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (bula de Carbinoxamina, Advertências e precauções)

Intervention: Concomitant use of VRAYLAR with a CYP3A4 inducer is not recommended [see Dosage and Administration ( 2.1 , 2.6 ) ] . (bula de Cariprazina, Interações medicamentosas)

Benzodiazepines, Opioid Analgesics, or other CNS Depressants : Concomitant use may result in profound sedation, respiratory depression, coma, or death. (bula de Cetamina, Interações medicamentosas)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (bula de Cetirizina, Advertências e precauções)

This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. (bula de Cetoconazol, Contraindicações)

Based on its structural similarity to TCAs, concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the… (bula de Ciclobenzaprina, Interações medicamentosas)

Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (bula de Ciprofloxacino, Interações medicamentosas)

Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (bula de Clonidina, Advertências e precauções)

• Concomitant use of Strong CYP3A4 Inducers is not recommended. (bula de Clozapina, Interações medicamentosas)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Codeína, Advertência em caixa preta)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (bula de Daridorexanto, Interações medicamentosas)

…elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance… (bula de Darunavir, Contraindicações)

Anticonvulsants with CYP3A induction effects that are NOT contraindicated: e.g. eslicarbazepine, oxcarbazepine ↓ cobicistat darunavir: effect unknown Consider alternative anticonvulsant or antiretroviral therapy to avoid potential changes in exposures. (bula de Darunavir + cobicistate, Interações medicamentosas)

If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

Avoid use of moderate or strong CYP3A4 inducers with EMFLAZA, as they may reduce efficacy ( 7.1 ) (bula de Deflazacorte, Interações medicamentosas)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (bula de Difenoxilato + atropina, Contraindicações)

Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

PIFELTRO is contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of PIFELTRO [see Warnings and Precautions (5.2) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ] . (bula de Doravirina, Contraindicações)

• Avoid concomitant use of doxorubicin hydrochloride with inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp ( 7.1 ) (bula de Doxorrubicina, Interações medicamentosas)

• CYP3A inducers: Avoid concomitant use. (bula de Dronedarona, Interações medicamentosas)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Alpha 1-adrenoreceptor antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine Herbal Products: St. (bula de Elvitegravir + cobicistate + entricitabina + tenofovir, Contraindicações)

…virologic response and possible resistance to COMPLERA or to the class of NNRTIs [see Warnings and Precautions (5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose)… (bula de Entricitabina + rilpivirina + tenofovir, Contraindicações)

The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (bula de Eszopiclona, Advertências e precauções)

IT IS NOT KNOWN WHETHER CONCOMITANT USE OF OTHER ANTIEPILEPTIC DRUGS AND/OR OTHER DRUGS AFFECT THE INCIDENCE OF HEPATIC FAILURE. (bula de Felbamato, Advertência em caixa preta)

Phenelzine sulfate should not be used in combination with dextromethorphan or with CNS depressants such as alcohol and certain narcotics. (bula de Fenelzina, Contraindicações)

• Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Fentanila, Advertência em caixa preta)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

…Hypericum perforatum ) Lipid modifying agents: Lomitapide, lovastatin, simvastatin Non-nucleoside reverse transcriptase inhibitor: Delavirdine PDE5 inhibitor: Sildenafil (Revatio) (for treatment of pulmonary arterial hypertension) Sedative/hypnotics: Midazolam, triazolam Hypersensitivity to fosamprenavir calcium or amprenavir (e.g., Stevens-Johnson syndrome). (bula de Fosamprenavir, Contraindicações)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Hidrocodona, Advertência em caixa preta)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION;… (bula de Hidrocodona + clorfeniramina, Advertência em caixa preta)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Hydrocodone bitartrate and homatropine methylbromide exposes patients and… (bula de Hidrocodona + homatropina, Advertência em caixa preta)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P4503A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE AND IBUPROFEN TABLETS Addiction,… (bula de Hidrocodona + ibuprofeno, Advertência em caixa preta)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Hidrocodona + paracetamol, Advertência em caixa preta)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death . (bula de Hidromorfona, Advertência em caixa preta)

Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (bula de Hidroxizina, Precauções)

• Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (bula de Irinotecano, Interações medicamentosas)

To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made 5,6 . (bula de Isoniazida, Interações medicamentosas)

Anticonvulsants Carbamazepine Not recommended 2 weeks before, during, and 2 weeks after TOLSURA treatment. (bula de Itraconazol, Interações medicamentosas)

Avoid concomitant use of CYP3A4 inducers when using Corlanor. (bula de Ivabradina, Interações medicamentosas)

Avoid strong CYP3A4 inducers. (bula de Lapatinibe, Interações medicamentosas)

Strong CYP3A4 Inducers: Avoid coadministration of strong CYP3A4 inducers with VITRAKVI. (bula de Larotrectinibe, Interações medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (bula de Lemborexanto, Interações medicamentosas)

Concomitant administration of SUNLENCA with strong CYP3A inducers is contraindicated due to decreased lenacapavir plasma concentrations, which may result in the loss of therapeutic effect and development of resistance to SUNLENCA [see Drug Interactions (7.1) ] . (bula de Lenacapavir, Contraindicações)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (bula de Levocetirizina, Advertências e precauções)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Levorfanol, Advertência em caixa preta)

…Non-opioid Analgesic (selective blocker of Nav1.8 sodium channels): suzetrigine PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension Sedative/Hypnotics: triazolam, orally administered midazolam KALETRA is contraindicated with drugs that are potent CYP3A inducers where significantly reduced lopinavir plasma concentrations… (bula de Lopinavir + ritonavir, Contraindicações)

Caution patients receiving LOREEV XR against operating machinery or driving a motor vehicle as well to avoid the concomitant use of alcohol and other CNS depressant drugs during treatment ( 5.4 , 7 ) (bula de Lorazepam, Advertências e precauções)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (bula de Lorlatinibe, Interações medicamentosas)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (bula de Lumateperona, Interações medicamentosas)

Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. (bula de Lurasidona, Contraindicações)

Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

Managing Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, is a risk factor for respiratory depression and death [see Warnings and Precautions ( 5.2 )]. (bula de Metadona, Advertência em caixa preta)

If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (bula de Metaxalona, Advertências e precauções)

WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS Personnel and Equipment for Monitoring and Resuscitation Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer… (bula de Midazolam, Advertência em caixa preta)

CYP3A inducers: Do not use mifepristone with CYP3A inducers ( 7.3 ). (bula de Mifepristona, Interações medicamentosas)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Morfina, Advertência em caixa preta)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Nalbufina, Advertência em caixa preta)

John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (bula de Naldemedina, Interações medicamentosas)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (bula de Nalmefeno, Advertências e precauções)

Strong CYP3A4 inducers (e.g., rifampin) : Decreased concentrations of naloxegol; concomitant use is not recommended. (bula de Naloxegol, Interações medicamentosas)

…(e.g., buprenorphine) use, or acute opiate withdrawal [see Warnings and Precautions (5.4) and Drug Interactions (7.2) ] Patients undergoing an abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions (5.3) and Drug Interactions (7.7) ] Concomitant administration of monoamine oxidase inhibitors (MAOI). (bula de Naltrexona + bupropiona, Contraindicações)

John’s Wort reduce the bioavailability and efficacy of nifedipine; therefore nifedipine should not be used in combination with strong CYP3A inducers such as rifampin (See CONTRAINDICATIONS ). (bula de Nifedipino, Interações medicamentosas)

Strong CYP3A Inducers: Avoid concomitant use with CAVHANZA. (bula de Nilotinibe, Interações medicamentosas)

…contraindicated with drugs that are primarily metabolized by CYP3A and for which elevated concentrations are associated with serious and/or life-threatening reactions and drugs that are strong CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. (bula de Nirmatrelvir + ritonavir, Contraindicações)

Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with COCs ( 7.1 ) -- - ---------- ------ USE IN SPECIFIC POPULATIONS---- -- -- --------- ---- Lactation: Not recommended; Lo Loestrin Fe can decrease milk production ( 8.2 ) (bula de Noretisterona + etinilestradiol, Interações medicamentosas)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Oliceridina, Advertência em caixa preta)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (bula de Olopatadina, Advertências e precauções)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (bula de Olopatadina + mometasona, Advertências e precauções)

APTIOM is contraindicated in patients with a hypersensitivity to eslicarbazepine acetate or oxcarbazepine [see Warnings and Precautions ( 5.2 , 5.3 , and 5.4 )]. (bula de Eslicarbazepina, Contraindicações)

Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions ( 5.2 )]. (bula de Oxibato de sódio, Advertência em caixa preta)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Oxicodona, Advertência em caixa preta)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Oxycodone hydrochloride tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (bula de Oxicodona + paracetamol, Advertência em caixa preta)

Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Oximorfona, Advertência em caixa preta)

• CYP3A Inducers: Avoid concurrent use of IBRANCE with strong CYP3A inducers. (bula de Palbociclibe, Interações medicamentosas)

Strong CYP3A4 and P-glycoprotein (P-gp) inducers : Avoid using a strong inducer of CYP3A4 and/or P-gp during a dosing interval for ERZOFRI. (bula de Paliperidona, Interações medicamentosas)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Paracetamol + codeína, Advertência em caixa preta)

VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (bula de Pazopanibe, Interações medicamentosas)

…MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Pentazocine and Naloxone Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (bula de Pentazocina + naloxona, Advertência em caixa preta)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Petidina (meperidina), Advertência em caixa preta)

Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of NUPLAZID. (bula de Pimavanserina, Interações medicamentosas)

• Patients taking strong Cytochrome P450 3A enzyme (CYP3A) inducers, such as rifampin, [see Warnings and Precautions ( 5.6 ) and Drug Interactions ( 7.1 , 7.2 )] . (bula de Praziquantel, Contraindicações)

…PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Promethazine HCl and Codeine Phosphate Oral Solution exposes patients and other users to the risks… (bula de Prometazina + codeína, Advertência em caixa preta)

If concomitant administration with carbamazepine or phenobarbital cannot be avoided, frequent monitoring of anticonvulsant drug concentrations is recommended. (bula de Quinina, Interações medicamentosas)

ASPRUZYO Sprinkle is contraindicated in patients: Taking strong inhibitors of CYP3A [see Drug Interactions (7.1)] Taking inducers of CYP3A [see Drug Interactions (7.1)] With liver cirrhosis [see Use in Specific Populations (8.6)] Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir) (4, 7.1) (bula de Ranolazina, Contraindicações)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Remifentanila, Advertência em caixa preta)

Table 2: Drugs That are Contraindicated with EDURANT and EDURANT PED Drug Class Contraindicated Drugs in Class Clinical Comment Anticonvulsants Carbamazepine Oxcarbazepine Phenobarbital Phenytoin Potential for significant decreases in rilpivirine plasma concentrations due to CYP3A enzyme induction, which may result in loss of virologic response. (bula de Rilpivirina, Contraindicações)

• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (bula de Rimegepanto, Interações medicamentosas)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (bula de Ritlecitinibe, Interações medicamentosas)

WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (bula de Ritonavir, Advertência em caixa preta)

Avoid concomitant use of XARELTO with drugs that are known combined P-gp and strong CYP3A inducers [see Drug Interactions (7.3) ] . (bula de Rivaroxabana, Advertências e precauções)

• Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

Intervention: Avoid the use of VARUBI in patients who require chronic administration of strong CYP3A4 inducers. (bula de Rolapitanto, Interações medicamentosas)

• Avoid use with rifampin and strong CYP3A4 inducers ( 7.3 ). (bula de Romidepsina, Interações medicamentosas)

Interaction with Strong Inhibitors and Inducers of CYP3A4 and/or P-gp Avoid concomitant use of sirolimus with strong inhibitors of CYP3A4 and/or P-gp (such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or P-gp (such as rifampin or rifabutin) [ see Drug Interactions (7.2) ]. (bula de Sirolimo, Advertências e precauções)

Anticonvulsants: carbamazepine phenytoin phenobarbital ↓ sofosbuvir ↓ velpatasvir ↓ voxilaprevir Coadministration is not recommended. (bula de Sofosbuvir + velpatasvir, Interações medicamentosas)

• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (bula de Tamoxifeno, Interações medicamentosas)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Tapentadol, Advertência em caixa preta)

Strong CYP3A4 inducers (e.g., rifampin): Avoid use of HETLIOZ in combination with rifampin or other CYP3A4 inducers, because of decreased exposure ( 7.2 , 12.3 ) (bula de Tasimelteona, Interações medicamentosas)

• Avoid use with strong CYP3A inhibitors or CYP3A inducers. (bula de Ticagrelor, Interações medicamentosas)

Avoid co-administration of strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) and strong CYP3A4 inducers (e.g., rifampin, phenytoin) with TEPADINA due to the potential effects on efficacy and toxicity [see Clinical Pharmacology ( 12.3 ) ] . (bula de Tiotepa, Interações medicamentosas)

Avoid concomitant use of SAMSCA with strong CYP3A inducers. (bula de Tolvaptana, Interações medicamentosas)

Coadministration with a strong CYP3A4 inducer may result in a relevant decrease in FARESTON exposure and should be avoided. (bula de Toremifeno, Interações medicamentosas)

CYP3A inducers: Avoid concomitant strong CYP3A inducers ( 7.1 ) (bula de Trabectedina, Interações medicamentosas)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Tramadol, Advertência em caixa preta)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Tramadol + paracetamol, Advertência em caixa preta)

Avoid concomitant use with strong CYP3A inducers if possible. (bula de Tretinoína, Interações medicamentosas)

• Effects on Driving and Operating Heavy Machinery : Patients receiving triazolam should be cautioned against driving or operating heavy machinery, as well as avoiding concomitant use with alcohol and other CNS depressant drugs. (bula de Triazolam, Advertências e precauções)

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (bula de Ubrogepanto, Interações medicamentosas)

Ella should not be administered with CYP3A4 inducers [see Drug interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Ulipristal, Advertências e precauções)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (bula de Upadacitinibe, Interações medicamentosas)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (bula de Valbenazina, Interações medicamentosas)

Strong CYP3A Inducers : Avoid concomitant use with strong CYP3A inducers. (bula de Vepdegestranto, Interações medicamentosas)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (bula de Zaleplona, Advertências)

The use of Zolpidem Tartrate with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended. (bula de Zolpidem, Advertências e precauções)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (bula de Acetazolamida, Interações medicamentosas)

Anticonvulsants Salicylic acid can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. (bula de Ácido acetilsalicílico + dipiridamol, Interações medicamentosas)

Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (bula de Albendazol, Advertências e precauções)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (bula de Alopurinol, Advertências e precauções)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (bula de Aminofilina, Interações medicamentosas)

Amoxapine may enhance the response to alcohol and the effects of barbiturates and other CNS depressants. (bula de Amoxapina, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Anlodipino, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Anlodipino + atorvastatina, Interações medicamentosas)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (bula de Anlodipino + benazepril, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Anlodipino + olmesartana, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e.g. rifampicin, St. (bula de Anlodipino + valsartana, Interações medicamentosas)

…cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine Monoamine Oxidase Inhibitors, Nonselective Beta-Adrenergic… (bula de Articaína + epinefrina, Interações medicamentosas)

CYP3A4/5 Inducers Co-administration of rifampin, a strong inducer of CYP3A4/5, reduced the plasma exposure of axitinib in healthy volunteers. (bula de Axitinibe, Interações medicamentosas)

Patients should also be cautioned that the central nervous system depressant effects of intrathecal baclofen may be additive to those of alcohol and other CNS depressants. (bula de Baclofeno, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (bula de Beclometasona, Advertências e precauções)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (bula de Bexagliflozina, Interações medicamentosas)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (bula de Brexpiprazol, Interações medicamentosas)

Use with CNS depressants may result in an additive or potentiating effect. (bula de Brimonidina, Interações medicamentosas)

Use with CNS depressants may result in an additive or potentiating effect. (bula de Brimonidina + timolol, Interações medicamentosas)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (bula de Bromocriptina, Interações medicamentosas)

Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (bula de Bronfeniramina + pseudoefedrina + dextrometorfano, Interações medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (bula de Bupivacaína, Advertências e precauções)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (bula de Bupivacaína + epinefrina, Advertências e precauções)

Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with buprenorphine and naloxone sublingual tablets [see Warnings and Precautions (5.3) , Drug Interactions (7) ] . (bula de Buprenorfina + naloxona, Advertências e precauções)

Triazolam/flurazepam: Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine. (bula de Buspirona, Interações medicamentosas)

Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. (bula de Butalbital + ácido acetilsalicílico + cafeína, Interações medicamentosas)

Butalbital and acetaminophen may enhance the effects of:other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. (bula de Butalbital + paracetamol, Interações medicamentosas)

Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. (bula de Butalbital + paracetamol + cafeína, Interações medicamentosas)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (bula de Canagliflozina, Interações medicamentosas)

• Additive sedative effects when used with other CNS depressants including alcohol (5.1) (bula de Carisoprodol, Advertências e precauções)

Inducers of Hepatic CYP Enzymes Rifampin : Rifampin is a potent CYP3A4 inducer and concomitant administration with caspofungin acetate for injection is expected to reduce the plasma concentrations of caspofungin acetate for injection. (bula de Caspofungina, Interações medicamentosas)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and oral corticosteroids) should be monitored and treated with established standards of care. (bula de Ciclesonida, Advertências e precauções)

Drugs/Dietary Supplements That Decrease Cyclosporine Concentrations Antibiotics Anticonvulsants Other Drugs/Dietary Supplements nafcillin carbamazepine bosentan St. (bula de Ciclosporina, Interações medicamentosas)

CYP2C19 Substrates APTIOM can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole) [see Clinical Pharmacology ( 12.3 )]. (bula de Eslicarbazepina, Interações medicamentosas)

CNS Depressants Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents. (bula de Ciproeptadina, Advertências)

Antiepileptics: Carbamazepine Use With Caution Carbamazepine: Concomitant administration of single doses of clarithromycin and carbamazepine has been shown to result in increased plasma concentrations of carbamazepine. (bula de Claritromicina, Interações medicamentosas)

Use with CNS Depressants Clemastine has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). Use in Activities Requiring Mental Alertness Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc. (bula de Clemastina, Advertências)

Inducers of CYP3A4 and CYP3A5 Inducers of CYP3A4 and/or CYP3A5 may reduce plasma concentrations of clindamycin. (bula de Clindamicina, Interações medicamentosas)

CYP2C19 Substrates APTIOM can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole) [see Clinical Pharmacology ( 12.3 )]. (bula de Eslicarbazepina, Interações medicamentosas)

…several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. (bula de Clomipramina, Interações medicamentosas)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. (bula de Clorazepato, Advertências)

The concomitant use of alcohol or other central nervous system depressants may have an additive effect. (bula de Clordiazepóxido, Advertências)

Effects on the Ability to Drive or Operate Machinery As in the case of other preparations containing CNS-acting drugs, patients receiving Librax should be cautioned about possible combined effects with opioids, alcohol and other CNS depressants. (bula de Clordiazepóxido + clidínio, Advertências)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (bula de Cloroprocaína, Precauções)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (bula de Clorpromazina, Precauções)

Chlorzoxazone use should also be discontinued if a patient develops abnormal liver enzymes (e.g., AST, ALT, alkaline phosphatase and bilirubin.) The concomitant use of alcohol or other central nervous system depressants may have an additive effect. (bula de Clorzoxazona, Advertências e precauções)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Use with CNS Depressants CORPHENA Oral Solution has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). Use in Activities Requiring Mental Alertness Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc. (bula de Dexclorfeniramina, Advertências)

Clinically Relevant Interactions Affecting DEXILANT When Coadministered with Other Drugs and Substances CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of dexlansoprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ] . (bula de Dexlansoprazol, Interações medicamentosas)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

As with other agents that have anticonvulsant activity, when Valium is used as an adjunct in treating convulsive disorders, the possibility of an increase in the frequency and/or severity of grand mal seizures may require an increase in the dosage of standard anticonvulsant medication. (bula de Diazepam, Advertências)

Exercise caution when prescribing ZIPSOR with concomitant drugs that are known to be potentially hepatotoxic (e.g., acetaminophen, antibiotics, antiepileptics). (bula de Diclofenaco, Advertências e precauções)

Exercise caution when prescribing diclofenac sodium/misoprostol with concomitant drugs that are known to be potentially hepatotoxic (e.g., antibiotics, anti-epileptics). (bula de Diclofenaco + misoprostol, Advertências e precauções)

Drug Interactions Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc). (bula de Difenidramina, Interações medicamentosas)

The concomitant use of alcohol or other central nervous system depressants may have an additive effect. (bula de Dimenidrinato, Advertências)

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (bula de Dofetilida, Interações medicamentosas)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (bula de Doxepina, Advertências e precauções)

Examples Glutethimide and phenobarbital Intervention If a patient initiates or discontinues therapy with an enzyme inducer, dose adjustment of doxercalciferol may be necessary. (bula de Doxercalciferol, Interações medicamentosas)

Barbiturates and Anti-Epileptics Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline. (bula de Doxiciclina, Interações medicamentosas)

Seizures and Seizure-like Activity : Weigh the potential risk versus benefits before prescribing dronabinol oral solution to patients with a history of seizures, including those requiring anti-epileptic medication or with other factors that lower the seizure threshold. (bula de Dronabinol, Advertências e precauções)

Following the administration of droperidol, the dose of other CNS depressant drugs should be reduced. (bula de Droperidol, Interações medicamentosas)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

CYP2C19 Substrates APTIOM can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole) [see Clinical Pharmacology ( 12.3 )]. (bula de Eslicarbazepina, Interações medicamentosas)

CYP2C19 Substrates APTIOM can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole) [see Clinical Pharmacology ( 12.3 )]. (bula de Eslicarbazepina, Interações medicamentosas)

Other Agents Anticonvulsants: carbamazepine oxcarbazepine phenobarbital phenytoin ↓ TAF Consider alternative anticonvulsant. (bula de Entricitabina + tenofovir, Interações medicamentosas)

CYP3A4 Inducers Pre-treatment with a CYP3A4 inducer prior to erlotinib decreased erlotinib exposure [see Clinical Pharmacology (12.3) ]. (bula de Erlotinibe, Interações medicamentosas)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (bula de Ertapeném, Advertências e precauções)

Weigh this potential risk against the benefits before prescribing TRANSDERM SCŌP to patients with a history of seizures, including those receiving anti-epileptic medication or who have risk factors that can lower the seizure threshold. (bula de Escopolamina, Advertências e precauções)

CYP2C19 Substrates APTIOM can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole) [see Clinical Pharmacology ( 12.3 )]. (bula de Eslicarbazepina, Interações medicamentosas)

Although behaviors such as sleep-driving may occur with sedative-hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with sedative-hypnotics appears to increase the risk of such behaviors, as does the use of sedative-hypnotics at doses exceeding the maximum recommended dose. (bula de Estazolam, Advertências)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

CYP2C19 Substrates APTIOM can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole) [see Clinical Pharmacology ( 12.3 )]. (bula de Eslicarbazepina, Interações medicamentosas)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (bula de Everolimo, Interações medicamentosas)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (bula de Exemestano, Interações medicamentosas)

Dose adjustment of simvastatin and lovastatin may be needed if a clinically significant change in lipids is noted. (bula de Eslicarbazepina, Interações medicamentosas)

Anticonvulsants - In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (e.g., phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers. (bula de Felodipino, Interações medicamentosas)

Phenytoin: Higher dosage of APTIOM may be necessary and dose adjustment may be needed for phenytoin. (bula de Eslicarbazepina, Interações medicamentosas)

Phenobarbital or Primidone: Higher dosage of APTIOM may be necessary. (bula de Eslicarbazepina, Interações medicamentosas)

Phenobarbital or Primidone: Higher dosage of APTIOM may be necessary. (bula de Eslicarbazepina, Interações medicamentosas)

Phenobarbital Clinical Impact: Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen. (bula de Fenoprofeno, Interações medicamentosas)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

CYP3A4 Inducers No dosing adjustments are recommended in the presence of CYP3A4 inducers, such as rifampin and carbamazepine. (bula de Fesoterodina, Interações medicamentosas)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (bula de Flecainida, Interações medicamentosas)

CYP2C19 Substrates APTIOM can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole) [see Clinical Pharmacology ( 12.3 )]. (bula de Eslicarbazepina, Interações medicamentosas)

Possible risk factors for seizures include: concurrent major sedative-hypnotic drug withdrawal, recent therapy with repeated doses of parenteral benzodiazepines, myoclonic jerking or seizure activity prior to flumazenil administration in overdose cases, or concurrent cyclic antidepressant poisoning. (bula de Flumazenil, Advertências)

Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity ( 7.7 ) (bula de Fluoxetina, Interações medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids), should be monitored and treated with established standards of care. (bula de Fluticasona, Advertências e precauções)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Fluticasona + salmeterol, Advertências e precauções)

CYP2C19 Substrates APTIOM can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole) [see Clinical Pharmacology ( 12.3 )]. (bula de Eslicarbazepina, Interações medicamentosas)

Effects of VYKOURA on Other Drugs Certain Antiepileptic Drugs Increase monitoring for seizure activity in patients taking certain concomitant antiepileptic drugs. (bula de Folinato de cálcio (leucovorina), Interações medicamentosas)

CYP3A4 Interactions: Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4; see Full Prescribing Information for recommendations regarding contraindications, risk of adverse reactions, and dosage adjustment of FOCINVEZ and concomitant drugs. (bula de Fosaprepitanto, Advertências e precauções)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

• CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (bula de Gefitinibe, Interações medicamentosas)

Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (bula de Glicopirrônio, Interações medicamentosas)

…and its plasma concentrations can be significantly affected resulting in an increase in exposure Consider dose reduction [see Dosage and administration (2.7) ] Strong and moderate CYP3A4 inducers, e.g., rifampin, efavirenz Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in a decrease in exposure… (bula de Guanfacina, Interações medicamentosas)

Drugs that May Decrease Haloperidol Plasma Concentrations Coadministration of haloperidol with potent enzyme inducers of CYP3A4 may gradually decrease the plasma concentrations of haloperidol to such an extent that efficacy may be reduced. (bula de Haloperidol, Interações medicamentosas)

Concomitant administration of inducers of CYP3A4 may lead to decreases in serum concentrations of ALKINDI SPRINKLE and increase the risk of adverse reactions, including adrenal crisis. (bula de Hidrocortisona, Interações medicamentosas)

• CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (bula de Ifosfamida, Interações medicamentosas)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (bula de Imatinibe, Interações medicamentosas)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of PRIMAXIN re-examined to determine whether it should be decreased, or the antibacterial drug discontinued ( 5.2 ). (bula de Imipeném + cilastatina, Advertências e precauções)

The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary. (bula de Imipramina, Interações medicamentosas)

Concomitant Use with CYP3A Inducers Use of KALYDECO with strong CYP3A inducers, such as rifampin, substantially decreases the exposure of ivacaftor, which may reduce the therapeutic effectiveness of KALYDECO. (bula de Ivacaftor, Advertências e precauções)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

Clinically Relevant Interactions Affecting PREVACID or PREVACID SoluTab When Coadministered with Other Drugs CYP2C19 OR CYP3A4 Inducers Clinical Impact: Decreased exposure of lansoprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ] . (bula de Lansoprazol, Interações medicamentosas)

Anticonvulsants: carbamazepine phenytoin phenobarbital ↓ ledipasvir ↓ sofosbuvir Coadministration of ledipasvir and sofosbuvir with carbamazepine, phenytoin, or phenobarbital is expected to decrease the concentration of ledipasvir and sofosbuvir, leading to reduced therapeutic effect of ledipasvir and sofosbuvir. (bula de Ledipasvir + sofosbuvir, Interações medicamentosas)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

Effects of Leucovorin Products on Other Drugs Antiepileptic Drugs Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone and increase the frequency of seizures in susceptible children. (bula de Levofolinato de cálcio (levoleucovorina), Interações medicamentosas)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

Abnormal Thyroid Function Tests Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM. (bula de Eslicarbazepina, Advertências e precauções)

Abnormal Thyroid Function Tests Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM. (bula de Eslicarbazepina, Advertências e precauções)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (bula de Lidocaína + epinefrina, Advertências e precauções)

…prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sufonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (bula de Lidocaína + prilocaína, Interações medicamentosas)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Inducers of P-glycoprotein or CYP3A4 Enzymes Clinical Impact Rifampin decreased linagliptin exposure, suggesting that the efficacy of linagliptin may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. (bula de Linagliptina + metformina, Interações medicamentosas)

Abnormal Thyroid Function Tests Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM. (bula de Eslicarbazepina, Advertências e precauções)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (bula de Lofexidina, Advertências e precauções)

Dose adjustment of simvastatin and lovastatin may be needed if a clinically significant change in lipids is noted. (bula de Eslicarbazepina, Interações medicamentosas)

• If patients with severe renal impairment or ESRD receiving SELZENTRY (without concomitant CYP3A inducers or inhibitors) experience postural hypotension, the dose of SELZENTRY should be reduced from 300 mg twice daily to 150 mg twice daily. (bula de Maraviroque, Advertências e precauções)

• Coadministration of meclizine hydrochloride with other CNS depressants, including alcohol, may result in increased CNS depression ( 7.1 ). (bula de Meclizina, Interações medicamentosas)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

Anticonvulsants In patients taking an anticonvulsant (e.g., valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant. (bula de Mefloquina, Interações medicamentosas)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (bula de Mepivacaína, Interações medicamentosas)

Additive Effects Since the effects of meprobamate and alcohol or meprobamate and other CNS depressants or psychotropic drugs may be additive,appropriate caution should be exercised with patients who take more than one of these agents simultaneously. (bula de Meprobamato, Advertências)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (bula de Metilergometrina, Interações medicamentosas)

Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin) : Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (bula de Metilprednisolona, Interações medicamentosas)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (bula de Metirosina, Interações medicamentosas)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (bula de Metocarbamol, Advertências e precauções)

John's Wort, tramadol, tryptophan, buspirone Strong CYP3A Inducers Clinical Impact The concomitant use of strong CYP3A inducers with REMERON/REMERONSolTab decreases the plasma concentration of mirtazapine [see Clinical Pharmacology (12.3) ] . (bula de Mirtazapina, Interações medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (bula de Mometasona, Advertências e precauções)

WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (bula de Naloxona, Advertências e precauções)

CYP2C19 Substrates APTIOM can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole) [see Clinical Pharmacology ( 12.3 )]. (bula de Eslicarbazepina, Interações medicamentosas)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (bula de Nevirapina, Interações medicamentosas)

Possible Reduced Efficacy with Strong CYP3A4 Inducers Concomitant use of strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, St. (bula de Nimodipino, Advertências e precauções)

Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (bula de Nintedanibe, Interações medicamentosas)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

Carbamazepine : Potential for elevated carbamazepine levels and clinical anticonvulsant toxicity ( 7.7 ) (bula de Olanzapina + fluoxetina, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

CYP2C19 Substrates APTIOM can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole) [see Clinical Pharmacology ( 12.3 )]. (bula de Eslicarbazepina, Interações medicamentosas)

CYP2C19 Substrates APTIOM can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole) [see Clinical Pharmacology ( 12.3 )]. (bula de Eslicarbazepina, Interações medicamentosas)

Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (bula de Ondansetrona, Interações medicamentosas)

Drug Interactions and Decreased Vitamin Absorption ORLISTAT may interact with concomitant drugs including cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, and antiretroviral drugs [see Drug Interactions (7) ]. (bula de Orlistate, Advertências e precauções)

Patients should be warned that the effects of alcohol or other CNS-depressant drugs may be additive to those of Oxazepam, possibly requiring adjustment of dosage or elimination of such agents. (bula de Oxazepam, Advertências)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

If the patient is being treated with an anticonvulsant agent, increased dosage of that agent may be required when perphenazine products are used concomitantly. (bula de Perfenazina, Advertências)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (bula de Pitolisanto, Interações medicamentosas)

Concomitant Use with Midazolam : Noxafil can prolong hypnotic/sedative effects. (bula de Posaconazol, Advertências e precauções)

CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (bula de Prednisolona, Interações medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (bula de Prednisona, Interações medicamentosas)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

…cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing… (bula de Prilocaína + epinefrina, Interações medicamentosas)

Phenobarbital or Primidone: Higher dosage of APTIOM may be necessary. (bula de Eslicarbazepina, Interações medicamentosas)

Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. (bula de Proclorperazina, Precauções)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (bula de Eslicarbazepina, Interações medicamentosas)

The impairment may be amplified by concomitant use of other central-nervous-system depressants such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore such agents should either be eliminated or given in reduced dosage in the presence of promethazine… (bula de Prometazina, Advertências)

The impairment may be amplified by concomitant use of other central-nervous-system depressants such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore such agents should either be eliminated or given in reduced dosage in the presence of promethazine… (bula de Prometazina + dextrometorfano, Advertências)

Abnormal Thyroid Function Tests Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM. (bula de Eslicarbazepina, Advertências e precauções)

As with other sedative medications, there is wide interpatient variability in DIPRIVAN dosage requirements, and these requirements may change with time. (bula de Propofol, Advertências e precauções)

Protriptyline may enhance the response to alcohol and the effects of barbiturates and other CNS depressants. (bula de Protriptilina, Interações medicamentosas)

• Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7-14 days) of potent CYP3A4 inducers (e.g., phenytoin, rifampin, St. (bula de Quetiapina, Interações medicamentosas)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (bula de Ramelteona, Advertências e precauções)

CYP2C8 and CYP3A4 Inducers Intervention: Repaglinide tablets dose increases and increased frequency of glucose monitoring may be required when co‑administered. (bula de Repaglinida, Interações medicamentosas)

Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. (bula de Rifabutina, Interações medicamentosas)

…Hormonal Contraceptives Prevention or Management: Advise patients to change to non-hormonal methods of birth control during rifampin therapy Estrogens Decrease exposure Progestins Anticonvulsants Phenytoin Administered with rifampin 450 mg daily Decrease exposure Antiarrhythmics Disopyramide Decrease exposure Mexiletine Decrease exposure Quinidine Decrease exposure… (bula de Rifampicina, Interações medicamentosas)

…Disopyramide, mexiletine, quinidine, tocainide Antibiotics Chloramphenicol, clarithromycin, dapsone, doxycycline; Fluoroquinolones (such as ciprofloxacin) Oral Anticoagulants Warfarin Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam… (bula de Rifapentina, Interações medicamentosas)

Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (bula de Risperidona, Interações medicamentosas)

Reduced Rocuronium Bromide Injection activity possible : Anticonvulsants. (bula de Rocurônio, Interações medicamentosas)

…cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine NAROPIN should be used with caution in patients receiving… (bula de Ropivacaína, Interações medicamentosas)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (bula de Ruxolitinibe, Interações medicamentosas)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (bula de Selegilina, Interações medicamentosas)

Dose adjustment of simvastatin and lovastatin may be needed if a clinically significant change in lipids is noted. (bula de Eslicarbazepina, Interações medicamentosas)

• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (bula de Sunitinibe, Interações medicamentosas)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (bula de Suvorexanto, Advertências e precauções)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (bula de Tacrolimo, Advertências e precauções)

CYP3A4 inhibitors (e.g. ketoconazole, ritonavir) increase CIALIS exposure ( 2.7 , 5.10 , 7.2 ) requiring dose adjustment: CIALIS for use as needed: no more than 10 mg every 72 hours CIALIS for once daily use: dose not to exceed 2.5 mg CYP3A4 inducers (e.g. rifampin) decrease CIALIS exposure ( 7.2 ). (bula de Tadalafila, Interações medicamentosas)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (bula de Telmisartana + anlodipino, Interações medicamentosas)

Although behaviors such as “sleep-driving” may occur with temazepam capsules alone at therapeutic doses, the use of alcohol and other CNS depressants with temazepam capsules appear to increase the risk of such behaviors, as does the use of temazepam capsules at doses exceeding the maximum recommended dose. (bula de Temazepam, Advertências)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (bula de Tensirolimo, Advertências e precauções)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (bula de Teofilina, Interações medicamentosas)

Terbinafine clearance is increased 100% by rifampin, a CYP450 enzyme inducer, and decreased 33% by cimetidine, a CYP450 enzyme inhibitor. (bula de Terbinafina, Interações medicamentosas)

Abnormal Thyroid Function Tests Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM. (bula de Eslicarbazepina, Advertências e precauções)

Alcohol or Other Sedating Drugs Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence [see Warnings and Precautions (5.7) ] . (bula de Tetrabenazina, Interações medicamentosas)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

Abnormal Thyroid Function Tests Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM. (bula de Eslicarbazepina, Advertências e precauções)

Phenytoin, fosphenytoin: Adjustment of anticonvulsant and/or tinidazole dose(s) may be needed ( 7.1, 7.2 ) (bula de Tinidazol, Interações medicamentosas)

DRUG INTERACTIONS Hepatic microsomal enzyme inducing agents, such as carbamazepine, were found to significantly increase the clearance of thiothixene. (bula de Tiotixeno, Interações medicamentosas)

Sedation: Zanaflex may interfere with everyday activities; sedative effects of Zanaflex, alcohol, and other central nervous system (CNS) depressants are additive ( 5.3 , 7.4 ) (bula de Tizanidina, Advertências e precauções)

…exposure to tofacitinib Intervention Dosage modification of XELJANZ/XELJANZ XR is recommended [see Dosage and Administration (2) , Clinical Pharmacology, Figure 3 (12.3) ] Strong CYP3A4 Inducers (e.g., rifampin) Clinical Impact Decreased exposure to tofacitinib and may result in loss of or reduced clinical response Intervention Concomitant use with XELJANZ/XELJANZ… (bula de Tofacitinibe, Interações medicamentosas)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

Excessive reduction of blood glucose (additive effect) f CNS depressant agents (including opioids, alcohol, sedatives, hypnotics) Use with caution d Increased CNS depression Dietary supplements containing sympathomimetics Contraindicated a Antidepressants including but not limited to: Other MAOIs (e.g., linezolid, intravenous methylene blue, selective MAOIs)… (bula de Tranilcipromina, Interações medicamentosas)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (bula de Trazodona, Interações medicamentosas)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (bula de Treprostinila, Advertências e precauções)

Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (bula de Triancinolona, Interações medicamentosas)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (bula de Triexifenidil, Interações medicamentosas)

Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. (bula de Trifluoperazina, Precauções)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (bula de Trimetobenzamida, Advertências e precauções)

CYP3A4 inducers decrease verapamil levels ( 7.1 ) (bula de Verapamil, Interações medicamentosas)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

CYP3A4 Inducers: Consider increasing VIIBRYD dosage by 2-fold, up to 80 mg once-daily over 1 to 2 weeks when used concomitantly with strong CYP3A4 inducers for greater than 14 days ( 2.4 , 7 ). (bula de Vilazodona, Interações medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (bula de Vincristina, Interações medicamentosas)

CYP2C19 Substrates APTIOM can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole) [see Clinical Pharmacology ( 12.3 )]. (bula de Eslicarbazepina, Interações medicamentosas)

Pharmacokinetic Interactions Carbamazepine Carbamazepine is an inducer of CYP3A4; administration of 200 mg twice daily for 21 days resulted in a decrease of approximately 35% in the AUC of ziprasidone. (bula de Ziprasidona, Interações medicamentosas)

Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. (bula de Eslicarbazepina, Advertências e precauções)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (bula de Alfaepoetina, Advertências e precauções)

Guanethidine or similarly acting compounds; thyroid medication; alcohol, barbiturates and other CNS depressants; and disulfiram – see WARNINGS section. (bula de Amitriptilina, Interações medicamentosas)

Anticonvulsant therapy can be given if clinically indicated. (bula de Cefalexina, Advertências e precauções)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (bula de Cefazolina, Advertências e precauções)

Antiepileptic Drugs Sporadic cases of seizures have been reported during concomitant use of ketorolac tromethamine and antiepileptic drugs (phenytoin, carbamazepine). (bula de Cetorolaco, Interações medicamentosas)

Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (bula de Dextroanfetamina, Interações medicamentosas)

Drug Interactions If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur. (bula de Disopiramida, Interações medicamentosas)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (bula de Docetaxel, Interações medicamentosas)

In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (bula de Doxapram, Advertências)

Concurrent use of alcohol and other CNS depressants (such as hypnotic sedatives and tranquilizers) with doxylamine succinate and pyridoxine hydrochloride delayed-release tablets is not recommended. (bula de Doxilamina + piridoxina, Interações medicamentosas)

Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (bula de Eribulina, Interações medicamentosas)

Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (bula de Escitalopram, Advertências e precauções)

Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (bula de Fenilbutirato de glicerol, Interações medicamentosas)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (bula de Hidroxicloroquina, Interações medicamentosas)

Therefore, ambulatory patients should be warned about activities requiring alertness (e.g., operating vehicles or machinery) and about concomitant use of alcohol and other CNS depressants. (bula de Loxapina, Advertências)

Anticonvulsants, psychotropic, hormone preparations, corticosteroids, antithyroid agents, cyproheptadine: may affect the results of the metyrapone test. (bula de Metirapona, Interações medicamentosas)

When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexiletine, lowered mexiletine plasma levels have been reported. (bula de Mexiletina, Interações medicamentosas)

…to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however),… (bula de Prazosina, Interações medicamentosas)

CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

Strong CYP3A inducers: Strong inducers of CYP3A (for example, rifampin, phenytoin, carbamazepine, phenobarbital or St. (bula de Riociguate, Interações medicamentosas)

These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (bula de Tesamorrelina, Interações medicamentosas)

Drugs Having No Clinically Important Interactions with SAPHRIS No dosage adjustment of SAPHRIS is necessary when administered concomitantly with paroxetine (see Table 12 in Drug Interactions ( 7.1 ) for paroxetine dosage adjustment), imipramine, cimetidine, valproate, lithium, or a CYP3A4 inducer (e.g., carbamazepine, phenytoin, rifampin). (bula de Asenapina, Interações medicamentosas)

CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. (bula de Micafungina, Interações medicamentosas)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (bula de Montelucaste, Interações medicamentosas)